Crystal Structure of the Androgen Receptor Ligand-binding Domain W741L Mutant Complex with R-bicalutamide

Experimental Data Snapshot

  • Resolution: 1.80 Å
  • R-Value Free: 0.256 
  • R-Value Work: 0.223 
  • R-Value Observed: 0.223 

wwPDB Validation   3D Report Full Report

Ligand Structure Quality Assessment 

This is version 1.4 of the entry. See complete history


Structural basis for antagonism and resistance of bicalutamide in prostate cancer.

Bohl, C.E.Gao, W.Miller, D.D.Bell, C.E.Dalton, J.T.

(2005) Proc Natl Acad Sci U S A 102: 6201-6206

  • DOI: https://doi.org/10.1073/pnas.0500381102
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 

    Carcinoma of the prostate is the most commonly diagnosed cancer in men. The current pharmacological treatment of choice for progressive androgen-dependent prostate cancer is the nonsteroidal antiandrogen, bicalutamide, either as monotherapy or with adjuvant castration or luteinizing hormone-releasing hormone superagonists to block the synthesis of endogenous testosterone. To date, no nonsteroidal or antagonist-bound androgen receptor (AR) structure is available. We solved the x-ray crystal structure of the mutant W741L AR ligand-binding domain bound to R-bicalutamide at 1.8-A resolution. This mutation confers agonist activity to bicalutamide and is likely involved in bicalutamide withdrawal syndrome. The three-dimensional structure demonstrates that the B ring of R-bicalutamide in the W741L mutant is accommodated at the location of the indole ring of Trp-741 in the WT AR bound to dihydrotestosterone. Knowledge of the binding mechanism for R-bicalutamide will provide molecular rationale for the development of new antiandrogens and selective AR modulators.

  • Organizational Affiliation

    Division of Pharmaceutics, College of Pharmacy, Ohio State University, Columbus, OH 43210, USA.

Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Androgen Receptor246Homo sapiensMutation(s): 1 
UniProt & NIH Common Fund Data Resources
Find proteins for P10275 (Homo sapiens)
Explore P10275 
Go to UniProtKB:  P10275
PHAROS:  P10275
GTEx:  ENSG00000169083 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupP10275
Sequence Annotations
  • Reference Sequence
Small Molecules
Binding Affinity Annotations 
IDSourceBinding Affinity
198 BindingDB:  1Z95 Ki: min: 11, max: 3700 (nM) from 3 assay(s)
IC50: min: 120.23, max: 490 (nM) from 4 assay(s)
EC50: 1000 (nM) from 1 assay(s)
PDBBind:  1Z95 Ki: 76 (nM) from 1 assay(s)
0U9 BindingDB:  1Z95 Ki: min: 14, max: 2460 (nM) from 13 assay(s)
IC50: min: 8.7, max: 1.20e+4 (nM) from 31 assay(s)
EC50: min: 157, max: 1.00e+4 (nM) from 4 assay(s)
Experimental Data & Validation

Experimental Data

  • Resolution: 1.80 Å
  • R-Value Free: 0.256 
  • R-Value Work: 0.223 
  • R-Value Observed: 0.223 
  • Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 56.49α = 90
b = 66.47β = 90
c = 72.16γ = 90
Software Package:
Software NamePurpose
crystaldata collection
d*TREKdata reduction
CrystalCleardata reduction
d*TREKdata scaling

Structure Validation

View Full Validation Report

Ligand Structure Quality Assessment 

Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2005-04-19
    Type: Initial release
  • Version 1.1: 2008-04-30
    Changes: Version format compliance
  • Version 1.2: 2011-07-13
    Changes: Version format compliance
  • Version 1.3: 2021-10-20
    Changes: Database references, Derived calculations
  • Version 1.4: 2023-08-23
    Changes: Data collection, Refinement description